These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 11067958)

  • 1. Triggering Fc alpha-receptor I (CD89) recruits neutrophils as effector cells for CD20-directed antibody therapy.
    Stockmeyer B; Dechant M; van Egmond M; Tutt AL; Sundarapandiyan K; Graziano RF; Repp R; Kalden JR; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol; 2000 Nov; 165(10):5954-61. PubMed ID: 11067958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of G-CSF- or GM-CSF-stimulated tumor cell killing by Fc receptor-directed bispecific antibodies.
    Stockmeyer B; Elsässer D; Dechant M; Repp R; Gramatzki M; Glennie MJ; van de Winkel JG; Valerius T
    J Immunol Methods; 2001 Feb; 248(1-2):103-11. PubMed ID: 11223072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FcalphaRI (CD89) as a novel trigger molecule for bispecific antibody therapy.
    Valerius T; Stockmeyer B; van Spriel AB; Graziano RF; van den Herik-Oudijk IE; Repp R; Deo YM; Lund J; Kalden JR; Gramatzki M; van de Winkel JG
    Blood; 1997 Dec; 90(11):4485-92. PubMed ID: 9373259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immature neutrophils mediate tumor cell killing via IgA but not IgG Fc receptors.
    Otten MA; Rudolph E; Dechant M; Tuk CW; Reijmers RM; Beelen RH; van de Winkel JG; van Egmond M
    J Immunol; 2005 May; 174(9):5472-80. PubMed ID: 15843545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of HER-2/neu-specific cytotoxic neutrophils in vivo: efficient arming of neutrophils by combined administration of granulocyte colony-stimulating factor and Fcgamma receptor I bispecific antibodies.
    Heijnen IA; Rijks LJ; Schiel A; Stockmeyer B; van Ojik HH; Dechant M; Valerius T; Keler T; Tutt AL; Glennie MJ; van Royen EA; Capel PJ; van de Winkel JG
    J Immunol; 1997 Dec; 159(11):5629-39. PubMed ID: 9548506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.
    Pascal V; Laffleur B; Debin A; Cuvillier A; van Egmond M; Drocourt D; Imbertie L; Pangault C; Tarte K; Tiraby G; Cogné M
    Haematologica; 2012 Nov; 97(11):1686-94. PubMed ID: 22689689
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective phagocytosis and killing of Candida albicans via targeting FcgammaRI (CD64) or FcalphaRI (CD89) on neutrophils.
    van Spriel AB; van den Herik-Oudijk IE; van Sorge NM; Vilé HA; van Strijp JA; van de Winkel JG
    J Infect Dis; 1999 Mar; 179(3):661-9. PubMed ID: 9952373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor immune effector mechanisms recruited by phage display-derived fully human IgG1 and IgA1 monoclonal antibodies.
    Huls G; Heijnen IA; Cuomo E; van der Linden J; Boel E; van de Winkel JG; Logtenberg T
    Cancer Res; 1999 Nov; 59(22):5778-84. PubMed ID: 10582699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhancement of polymorphonuclear cell-mediated tumor cell killing on simultaneous engagement of fcgammaRI (CD64) and fcalphaRI (CD89).
    van Egmond M; van Spriel AB; Vermeulen H; Huls G; van Garderen E; van de Winkel JG
    Cancer Res; 2001 May; 61(10):4055-60. PubMed ID: 11358825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epidermal growth factor receptor and g250: useful target antigens for antibody mediated cellular cytotoxicity against renal cell carcinoma?
    Stadick H; Stockmeyer B; Kühn R; Schrott KM; Kalden JR; Glennie MJ; van de Winkel JG; Gramatzki M; Valerius T; Elsässer D
    J Urol; 2002 Feb; 167(2 Pt 1):707-12. PubMed ID: 11792958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody.
    Stockmeyer B; Schiller M; Repp R; Lorenz HM; Kalden JR; Gramatzki M; Valerius T
    Br J Haematol; 2002 Sep; 118(4):959-67. PubMed ID: 12199773
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating antibodies for their capacity to induce cell-mediated lysis of malignant B cells.
    Würflein D; Dechant M; Stockmeyer B; Tutt AL; Hu P; Repp R; Kalden JR; van de Winkel JG; Epstein AL; Valerius T; Glennie M; Gramatzki M
    Cancer Res; 1998 Jul; 58(14):3051-8. PubMed ID: 9679970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
    Chen J; Zhou JH; Ball ED
    Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of antibody-dependent cell-mediated cytotoxicity by endowing IgG with FcαRI (CD89) binding.
    Borrok MJ; Luheshi NM; Beyaz N; Davies GC; Legg JW; Wu H; Dall'Acqua WF; Tsui P
    MAbs; 2015; 7(4):743-51. PubMed ID: 25970007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific molecules directed to the Fc receptor for IgA (Fc alpha RI, CD89) and tumor antigens efficiently promote cell-mediated cytotoxicity of tumor targets in whole blood.
    Deo YM; Sundarapandiyan K; Keler T; Wallace PK; Graziano RF
    J Immunol; 1998 Feb; 160(4):1677-86. PubMed ID: 9469424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
    Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
    J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The novel tribody [(CD20)(2)xCD16] efficiently triggers effector cell-mediated lysis of malignant B cells.
    Glorius P; Baerenwaldt A; Kellner C; Staudinger M; Dechant M; Stauch M; Beurskens FJ; Parren PW; Winkel JG; Valerius T; Humpe A; Repp R; Gramatzki M; Nimmerjahn F; Peipp M
    Leukemia; 2013 Jan; 27(1):190-201. PubMed ID: 22660187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of CD20-dependent cellular cytotoxicity by G-CSF-stimulated neutrophils.
    van der Kolk LE; de Haas M; Grillo-López AJ; Baars JW; van Oers MH
    Leukemia; 2002 Apr; 16(4):693-9. PubMed ID: 11960351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lysis of murine B lymphoma cells by transgenic phagocytes via a human Fc gamma RI x murine MHC class II bispecific antibody.
    Heijnen IA; Glennie MJ; van de Winkel JG
    Cancer Immunol Immunother; 1997; 45(3-4):166-70. PubMed ID: 9435865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.